Literature DB >> 12964010

Factors influencing the expression of endogenous reverse transcriptases and viral-like 30 elements in mouse NIH3T3 cells.

Theodore Tzavaras1, Sofia Eftaxia, Sotiria Tavoulari, Paraskevi Hatzi, Charalambos Angelidis.   

Abstract

Retroviral reverse transcriptase (RT) plays a definite role in retroviral life cycle and is essential for the process of retrotransposition. We investigated the RNA expression of endogenous reverse transcriptases (enRTs) in the NIH3T3 mouse genome using, as a probe, a mixture of RT-PCR generated reverse transcriptase products potentially detecting a large number of RTs following treatment with different agents. We found that the expression of enRTs is induced approximately 500-fold following 5'-azacytidine-treatment. Amongst steroid hormones used such as estradiol, diethylstilbestrol, progesterone and dexamethasone only the latter was effective in inducing enRTs up to 4-fold at a concentration of 10(-7) M. Expression of a mouse dominant-negative form of p53 protein in cell clones resulted in induction of 20- to 50-fold, whereas C2-ceramide in a 4-fold induction at concentrations of 20-80 micro M. In a parallel analysis, the respective expression of the transposable viral-like 30 elements (VL30s) was also measured. Their expression was induced up to 50-fold by 5'-azacytidine, overexpression of the p53 gene and C2-ceramide at 80 micro M. It was also induced approximately 3- to 5-fold following estradiol, diethylstilbestrol or progesterone treatment and 30-fold by dexamethasone. Collectively, our results suggest that such stimuli inducing enRTs might play a role in the activation of transcription and retrotransposition of VL30.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964010

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Normal and pathological functions of mammalian retroelements.

Authors:  Albert Deisseroth
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

2.  Roles of PSF protein and VL30 RNA in reversible gene regulation.

Authors:  Xu Song; Ying Sun; Alan Garen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-03       Impact factor: 11.205

3.  Epigenetic regulation of a murine retrotransposon by a dual histone modification mark.

Authors:  Reinhard Brunmeir; Sabine Lagger; Elisabeth Simboeck; Anna Sawicka; Gerda Egger; Astrid Hagelkruys; Yu Zhang; Patrick Matthias; Wolfgang J Miller; Christian Seiser
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

4.  Application of a Modified Smart-seq2 Sample Preparation Protocol for Rare Cell Full-length Single-cell mRNA Sequencing to Mouse Oocytes.

Authors:  Rebecca S Treger; Scott D Pope; Xiaojun Xing; Akiko Iwasaki
Journal:  Bio Protoc       Date:  2019-08-20

5.  Genomic analysis of mouse VL30 retrotransposons.

Authors:  Georgios Markopoulos; Dimitrios Noutsopoulos; Stefania Mantziou; Demetrios Gerogiannis; Soteroula Thrasyvoulou; Georgios Vartholomatos; Evangelos Kolettas; Theodore Tzavaras
Journal:  Mob DNA       Date:  2016-05-06

6.  Tinzaparin inhibits VL30 retrotransposition induced by oxidative stress and/or VEGF in HC11 mouse progenitor mammary cells: Association between inhibition of cancer stem cell proliferation and mammosphere disaggregation.

Authors:  Stefania Mantziou; Georgios Markopoulos; Soteroula Thrasyvoulou; Dimitrios Noutsopoulos; Foteini Gkartziou; Georgios Vartholomatos; Theodore Tzavaras
Journal:  Oncol Rep       Date:  2021-09-24       Impact factor: 3.906

7.  VL30 retrotransposition is associated with induced EMT, CSC generation and tumorigenesis in HC11 mouse mammary stem‑like epithelial cells.

Authors:  Soteroula Thrasyvoulou; Georgios Vartholomatos; Georgios Markopoulos; Dimitrios Noutsopoulos; Stefania Mantziou; Foteini Gkartziou; Panagiotis Papageorgis; Antonia Charchanti; Panos Kouklis; Andreas I Constantinou; Theodore Tzavaras
Journal:  Oncol Rep       Date:  2020-04-28       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.